{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:16Z","timestamp":1790375356343,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.7759\/cureus.88032","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T02:39:08Z","timestamp":1752633548000},"source":"Crossref","is-referenced-by-count":1,"title":["Splenic Infarction at the Crossroads of Hematologic and Cardioembolic Risk"],"prefix":"10.7759","author":[{"given":"George K","family":"Annan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch","family":"Enninful","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Dwommoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye","family":"Egwuonwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Chapagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001363","article-title":"Acute splenic infarction at an academic general hospital over 10 years: presentation, etiology, and outcome","author":"Schattner A","year":"2015","unstructured":"Schattner A, Adi M, Kitroser E, Klepfish A. Acute splenic infarction at an academic general hospital over 10 years: presentation, etiology, and outcome. Medicine (Baltimore). 2015. 94:e1363. 10.1097\/MD.0000000000001363"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2018.1492148","article-title":"A practical approach to infarction of the spleen as a rare manifestation of multiple common diseases","volume":"50","author":"Wand O","year":"2018","unstructured":"Wand O, Tayer-Shifman OE, Khoury S, Hershko AY. A practical approach to infarction of the spleen as a rare manifestation of multiple common diseases. Ann Med. 2018, 50:494-500. 10.1080\/07853890.2018.1492148","journal-title":"Ann Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00897-0","article-title":"Risk assessment and prognostic analysis of patients with splenic infarction in emergency department: a multicenter retrospective study","volume":"11","author":"Yen CC","year":"2021","unstructured":"Yen CC, Wang CK, Chen SY, Gao SY, Lo HY, Ng CJ, Chaou CH. Risk assessment and prognostic analysis of patients with splenic infarction in emergency department: a multicenter retrospective study. Sci Rep. 2021, 11:21423. 10.1038\/s41598-021-00897-0","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94 Suppl 2","author":"Chereda B","year":"2015","unstructured":"Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015, 94 Suppl 2:S107-21. 10.1007\/s00277-015-2325-z","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour E","year":"2025","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: a review. JAMA. 2025, 333:1618-29. 10.1001\/jama.2025.0220","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131703","article-title":"Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights","volume":"12","author":"Iezza M","year":"2023","unstructured":"Iezza M, Cortesi S, Ottaviani E, et al.. Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights. Cells. 2023, 12:10.3390\/cells12131703","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13000","article-title":"The underestimated role of basophils in Ph(+) chronic myeloid leukaemia","volume":"48","author":"Valent P","year":"2018","unstructured":"Valent P, Horny HP, Arock M. The underestimated role of basophils in Ph(+) chronic myeloid leukaemia. Eur J Clin Invest. 2018, 48:e13000. 10.1111\/eci.13000","journal-title":"Eur J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1079262","article-title":"Hypercoagulability and tissue factor gene upregulation in hematologic malignancies","volume":"34","author":"Falanga A","year":"2008","unstructured":"Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008, 34:204-10. 10.1055\/s-2008-1079262","journal-title":"Semin Thromb Hemost"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1207395","article-title":"Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms","volume":"11","author":"Bekendam RH","year":"2023","unstructured":"Bekendam RH, Ravid K. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms. Front Cell Dev Biol. 2023, 11:1207395. 10.3389\/fcell.2023.1207395","journal-title":"Front Cell Dev Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-a puzzle still to be solved","volume":"23","author":"Bhuria V","year":"2022","unstructured":"Bhuria V, Baldauf CK, Schraven B, Fischer T. Thromboinflammation in myeloproliferative neoplasms (MPN)-a puzzle still to be solved. Int J Mol Sci. 2022, 23:10.3390\/ijms23063206","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247753","article-title":"Atrial fibrillation and cancer-epidemiology, mechanisms, and management","volume":"13","author":"Davis NE","year":"2024","unstructured":"Davis NE, Prasitlumkum N, Tan NY. Atrial fibrillation and cancer-epidemiology, mechanisms, and management. J Clin Med. 2024, 13:10.3390\/jcm13247753","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology","volume":"35","author":"Chu G","year":"2019","unstructured":"Chu G, Versteeg HH, Verschoor AJ, et al.. Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology. Blood Rev. 2019, 35:59-67. 10.1016\/j.blre.2019.03.005","journal-title":"Blood Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-025-03104-3","article-title":"Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions","author":"Seth L","year":"2025","unstructured":"Seth L, Stabellini N, Doss S, et al.. Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions. J Thromb Thrombolysis. 2025, 10.1007\/s11239-025-03104-3","journal-title":"J Thromb Thrombolysis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024, 149:e1-e156. 10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association","volume":"144","author":"Fradley MG","year":"2021","unstructured":"Fradley MG, Beckie TM, Brown SA, et al.. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021, 144:e41-55. 10.1161\/CIR.0000000000000986","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori D","year":"2021","unstructured":"Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GY, Fauchier L. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer. 2021, 127:2122-9. 10.1002\/cncr.33470","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00980-w","article-title":"Concomitant administration of direct oral anticoagulants in chronic phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"40","author":"Serrao A","year":"2020","unstructured":"Serrao A, Scalzulli E, Fiori L, Di Prima A, Breccia M, Chistolini A. Concomitant administration of direct oral anticoagulants in chronic phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Clin Drug Investig. 2020, 40:1177-81. 10.1007\/s40261-020-00980-w","journal-title":"Clin Drug Investig"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00566-5","article-title":"Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients","volume":"11","author":"How J","year":"2021","unstructured":"How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS, Connors JM. Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J. 2021, 11:176. 10.1038\/s41408-021-00566-5","journal-title":"Blood Cancer J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016984","article-title":"Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: a case report","volume":"98","author":"Wang Y","year":"2019","unstructured":"Wang Y, Wang L, Xi Y, Li Z. Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: a case report. Medicine (Baltimore). 2019, 98:e16984. 10.1097\/MD.0000000000016984","journal-title":"Medicine (Baltimore)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000817","article-title":"Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia","volume":"30","author":"Nair RR","year":"2019","unstructured":"Nair RR, Chauhan R, Harankhedkar S, Mahapatra M, Saxena R. Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia. Blood Coagul Fibrinolysis. 2019, 30:246-8. 10.1097\/MBC.0000000000000817","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2025.109284","article-title":"Association between anticoagulant-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism","volume":"248","author":"Wang TF","year":"2025","unstructured":"Wang TF, Luo S, Gage BF, et al.. Association between anticoagulant-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism. Thromb Res. 2025, 248:109284. 10.1016\/j.thromres.2025.109284","journal-title":"Thromb Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03480-8","article-title":"International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli U","year":"2023","unstructured":"Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, Kvasnicka HM. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023, 482:53-68. 10.1007\/s00428-022-03480-8","journal-title":"Virchows Arch"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1176","article-title":"Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: The KP-RHYTHM study","volume":"3","author":"Go AS","year":"2018","unstructured":"Go AS, Reynolds K, Yang J, et al.. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: The KP-RHYTHM study. JAMA Cardiol. 2018, 3:601-8. 10.1001\/jamacardio.2018.1176","journal-title":"JAMA Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010947","article-title":"Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi Atrial Fibrillation Registry","volume":"46","author":"Takabayashi K","year":"2015","unstructured":"Takabayashi K, Hamatani Y, Yamashita Y, et al.. Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Stroke. 2015, 46:3354-61. 10.1161\/STROKEAHA.115.010947","journal-title":"Stroke"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-197906000-00003","article-title":"Spleen size and chromosome analysis as prognostic factors in chronic myelogenous leukemia","volume":"72","author":"Collins RK","year":"1979","unstructured":"Collins RK, Jackson JF, Morrison FS, Meydrech EF. Spleen size and chromosome analysis as prognostic factors in chronic myelogenous leukemia. South Med J. 1979, 72:642-4, 651. 10.1097\/00007611-197906000-00003","journal-title":"South Med J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389261-splenic-infarction-at-the-crossroads-of-hematologic-and-cardioembolic-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T02:39:10Z","timestamp":1752633550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389261-splenic-infarction-at-the-crossroads-of-hematologic-and-cardioembolic-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.88032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}